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Abstract
The work in this thesis entitled “Enantioselective synthesis of biologically active compounds by chemoenzymatic approach and development of monastrol based new anti-cancer agents” has been undertaken with an aim to develop new chemoenzymatic routes that provides access to individual isomers of bio-active molecules and intermediates. Further, the other objective is to synthesize new molecules based on monastrol scaffold and the evaluation of their cytotoxic potency. The work carried out has been described in four chapters.
Chapter-1: Introduction - Biocatalysis and Cancer
This chapter provides a brief account on the field of biocatalysis and their applications in organic synthesis for various stereoselective transformations. Further, the opportunities and challenges faced by biocatalysis on industrial scale are discussed. In addition to this, it provides a concise account on cancer and the chemotherapeutic drugs used in its treatment.
Chapter-2: This chapter describes an efficient enantioselective synthesis of the some biologically active bisabolene sesquiterpenes type of natural products by lipase-mediated kinetic resolution and is divided into two sections. 
Section-A: Enantioselective Synthesis of R- and S- Curcumene and Curcuphenol by Chemoenzymatic Approach
Section-A deals with the synthesis of enantiomeric pairs of curcumene and curcuphenol by lipase-mediated kinetic resolution in high enantiopurity. The (S)- (+)-curcumene (1) is the simplest member of the bisabolene family of sesquiterpenes and both the R, S forms are present in nature. The phenolic sesquiterpene (S)-curcuphenol (2) is a major metabolite in different sponges and exhibits diverse biological activities such as H+/K+-ATPase inhibitory, cytotoxic, antiplasmodial activity. Interestingly, its enantiomer (-)-curcuphenol isolated from gorgorian coral shows antibacterial activity. In recent years, dimers of (S)-curcuphenol (e.g., 3) have been isolated and biologically evaluated. Further, the structure activity relationship studies of (S)-curcuphenol (3) have provided interesting results (Figure-1).

Figure 1
	The synthetic approach to these sesquiterpenoids starts with commercially available substituted acetophenones like 4-methyl-2-hydroxy acetophenone (4) and 4-methyl acetophenone (5a). The compound 4 is protected as the methyl ether to provide 5b and the acetophenones (5a, 5b) are converted to α, β-unsaturated esters (6a, 6b) by Horner-Wadsworth–Emmons reaction. The reduction of olefinic bond of the unsaturated esters by catalytic hydrogenation provides the required key intermediates (7a, 7b) as depicted in Scheme 1.
Scheme 1
Reagents and conditions: i) Me2SO4, K2CO3, acetone, reflux; ii) NaH, (EtO)2POCH2CO2Et, THF, reflux; iii) H2, 10% Pd-C, MeOH, rt.
An extensive investigation has been undertaken to develop an efficient resolution protocol in aqueous as well as organic media with esters (7a, 7b) and alcohols (9a, 9b). Based on these studies, the lipase-catalyzed hydrolysis of the racemic substituted ethyl butanoates (7a, 7b) have been performed employing the lipase from Pseudomonas cepacia immobilized on ceramic particles (PS-C) to provide the required acids (S)-8a, (S)-8b in high enantiopurity (>99% ee) and the remaining esters (R)-7a, (R)-7b with 92% ee and 94% ee respectively (Scheme 2).
Scheme 2

Reagents and conditions: i) lipase PS-C, phosphate buffer pH 7, 30 ºC.
		The enantiomerically pure S-acids and R-esters obtained by lipase mediated resolution are utilized in the total synthesis of the target compounds curcumene as well as curcuphenol in both R and S forms (Scheme 3). The reduction of the acids (S)-8a, (S)-8b provides the corresponding primary alcohols (S)-9a, (S)-9b, which are transformed to tosylates (S)-10a, (S)-10b, followed by cross coupling with 2-methyl-1-propenyl magnesium bromide to give the  desired  (S)-curcumene (1)  and  methylated  curcuphenol  (S)-11.  Finally, the cleavage of curcuphenol methyl ether (S)-11 affords the desired (S)-curcuphenol (2). The other enantiomers of the target compounds, (R)-1 and (R)-2 have also been synthesized from (R)-7a, (R)-7b following a similar synthetic route.
Scheme 3



Reagents and conditions: i) LAH; THF, rt; ii) TsCl, TEA, DMAP, CH2Cl2, rt; iii) 2-methyl-1-propenyl magnesium bromide, CuBr.Me2S, THF, -60 ºC; iv) BBr3, CH2Cl2, -78 ºC.

Section-B: Total Synthesis of R- and S- ar-Turmerone, (7S, 9R)-Bisacumol and (7S, 9S)-epi-Bisacumol by Chemoenzymatic Approach
This section describes a chemoenzymatic procedure for the total synthesis of optically pure R- and S- turmerone (12), (7S, 9R)-bisacumol (13) and its unnatural isomer (7S, 9S)-epi-bisacumol (13). The (S)-(+)-ar-turmerone (12), is one of the primary constituents of the essential oils obtained from the rhizomes of Curcuma longa and is reported to exhibits cytotoxic, anti-inflammatory, inhibition of platelet aggregation and anti-venom properties. Its unnatural isomer (R)-12 is a precursor of (R)-ar-himachalene (14), a sex pheromone of the flea beetle Aphthona flava. The other sesquiterpene (7S, 9R)-bisacumol (13) isolated from the rhizomes of Curcuma xanthorrhiza exhibits good cytotoxic activity, particularly against leukemia cell (Figure 2).

Figure 2
	In the present synthetic approach towards the synthesis of the target compounds, the enantiomerically pure acid (S)-8a and ester (R)-7a obtained by the lipase-mediated resolution of the racemic substituted butanoate ester 7a has been utilized. The acid (S)-8a is reduced to primary alcohol (S)-9a, followed by oxidation using Swern protocol to provide the aldehyde (S)-15, which is transformed to a diastereomeric mixture of bisacumol (7S)-13 by nucleophilic addition with 2-methyl-1-propenyl magnesium bromide. The Swern oxidation of (7S)-13 affords the naturally occurring (S)-turmerone (12). The unnatural isomer (R)-12, the precursor of (R)-himachalene (14) has been synthesized from the enantiopure substituted ester (R)-7a by employing a similar sequential route (Scheme 4).
Scheme 4

Reagents and conditions: i) LAH; THF, rt; ii) (COCl)2, DMSO, TEA, CH2Cl2, -78 ºC; iii) 2-methyl-1-propenyl magnesium bromide, THF, -60 ºC.
	In the total synthesis of the naturally occurring cytotoxic (7S, 9R)-bisacumol (13), the acetate (7S)-16 has been subjected to lipase-catalyzed hydrolysis. Extensive studies have been undertaken to obtain the naturally occurring target compound (7S, 9R)-bisacumol (13) in high enantiopurity. The lipase from Pseudomonas cepacia immobilized on ceramic particles (PS-C) has provided the (7S, 9R)-bisacumol (13) in 94% ee and the acetate (7S, 9S)-16 in 62% ee, which has been deacetylated to provide (7S, 9S)-epi-bisacumol 13 (Scheme 5).
Scheme 5
Reagents and conditions: i) Ac2O, Et3N, CH2Cl2, rt; ii) lipase PS-C, phosphate buffer pH 7, 30 ºC; iii) anhydrous K2CO3, CH3OH, rt
Chapter-3: This chapter describes the enantioselective synthesis of chiral -azidoalcohols by employing lipase-catalyzed resolution and their application in the synthesis of enantiomeric pairs of antidepressant drugs like fluoxetine and duloxetine. This chapter is further divided into two sections.
Section-A: Synthesis of Enantiomerically Pure -Azidoalcohols by Lipase Catalyzed Transesterification
Section A demonstrates the enantioselective synthesis of chiral -azidoalcohols by employing lipase catalyzed transesterification process and the studies on the efficiency of various lipases as well as the effect of different solvents. The chiral -aminoalcohols are important structural units in many natural products, pharmacologically useful drugs and chiral ligands or auxiliaries that are useful in stereoselective synthesis. The -azidoalcohols are immediate precursors of -aminoalcohols, apart from β-hydroxynitriles and are useful in asymmetric Schmidt reaction (Figure 3). 

Figure 3
The racemic -azidoalcohols (18a-f), the intermediates required for the investigations for the development of a lipase-mediated kinetic resolution process are synthesized from various substituted benzenes 17 and thiophene (17’). The efficiency of various lipases and the effect of different solvents have been studied. The lipase from Pseudomonas cepacia immobilized on diatomaceous earth (PS-D) catalyzed the transesterification process in an efficient manner to provide the optically pure -azidoalcohols (S)-18a-f in high enantiomeric excess (96->99% ee) and the corresponding azidoacetates (R)-19a-f in 76->99% ee (Scheme 6).
Scheme 6

Reagents and conditions: i) lipase PS-D, IPA, n-hexane.
Section-B: Lipase mediated Resolution of -Azidoacetates in Aqueous and Organic media: Synthesis of (R)- and (S)- Fluoxetine and Duloxetine
This section deals with the studies undertaken in the lipase catalyzed kinetic resolutions of acetates of -azidoalcohols in aqueous as well as organic media and the synthesis of enantiomeric pairs of fluoxetine and duloxetine. The selective serotonin/norepinephrine reuptake inhibitors like fluoxetine (20), tomoxetine (21), nisoxetine (22), duloxetine (23) and (R)-N- [3-(4’-fluorophenyl)-3-(4’-phenylphenoxy) propyl]-sarcosine (24) used for the treatment of impulse control disorders contains -aminoalcohol subunits, which can be obtained by the reduction of -azidoalcohol (Figure 4).
 Figure 4
	The kinetic resolution of racemic acetates (19a, 19f) in aqueous and organic media with various lipases has been investigated. In the hydrolysis of acetates in aqueous medium, the lipase PS-C has been found to give good selectivity providing azidoacetates (S)-19a and (S)-19f in 97% ee and 94% ee, respectively. The alcoholysis of acetates (19a, 19f) using n-butanol in n-hexane provides the azidoalcohols (R)-18a and (R)-18f in 99% ee and 90% ee, respectively (Scheme 7).
Scheme 7

Reagents and conditions: i) lipase PS-C, phosphate buffer pH 7 (or) PS-C,
 n-butanol, n-hexane.
Based on the investigations of the kinetic resolution of -azidoalcohols and their acetates, on a preparative scale, the lipase mediated transesterification of the racemic -azidoalcohols 18a and 18f has been selected for the synthesis of enantiomeric pairs of target drugs. The lipase from P. cepacia (PS-D) provides the required alcohols (S)-18a and (S)-18f in high enantiopurity (>99% ee and 95% ee, respectively) and the acetate (R)-19a and (R)-19f in 93% ee and 75% ee, respectively. The chiral -azidoalcohols (S)-18a and (S)-18f are reduced by catalytic hydrogenation to -aminoalcohols, which without isolation have been converted to their corresponding ethyl carbamates (S)-25a and (S)-25f. The carbamates on reduction provide the N-monomethylated amino alcohols (S)-26a and (S)-26f, which on etherification affords the enantiopure anti-depressant drugs, (S)-fluoxetine (20) and (S)-duloxetine (23) (Scheme 8). Similarly, the other enantiomers are prepared from R-azidoalcohols.
Scheme 8


Reagents and conditions: i) H2, 10% Pd-C, MeOH; ii) ethyl chloroformate, K2CO3, CH2Cl2; iii) LAH, THF; iv) 4-chlorobenzotrifluoride, NaH, DMSO; v) 1-fluoronapthalene, NaH, DMSO.
Chapter-4: This chapter describes the design and synthesis of monastrol based new anti-cancer agents and has been further divided into two sections.
Section A: Structurally Modified Monastrol based Compounds as Potential Anti-Cancer Agents
The section-A deals with the synthesis of structurally modified monastrol based compounds and their cytotoxicity evaluation on a panel of human cancer cell lines. The antimitotic cancer drugs, such as taxol, targeting spindle microtubules shows neurotoxicity as microtubules plays a broader role in cellular processes. This underscores the need for specific targets and kinesins, the mechanochemical enzymes that utilize the energy of ATP to translocate along or destabilize microtubules, are emerging as new mitotic targets in cancer therapy. Monastrol (27) is the first Eg5 kinesis inhibitor to be identified and has led to the discovery as well as development of more potent Eg5 inhibitors such as dimethylenastron (28), S-trityl-L-cysteine (29) and Ispinesib (30) (Figure 5).
Figure 5
It is considered of interest to incorporate amino acids such as proline and cyclic cysteine (containing thiazolidine ring) to a monastrol type of scaffold. In this regard a number of proline and thiazolidine conjugates of monastrol based dihydropyrimidones have been synthesized and explored for their anti-cancer activity. The required precursors with-ketoamide functionality (33, 38) for these compounds are synthesized by utilizing the naturally occurring amino acids proline and cysteine as shown in Scheme 9. The methylation of proline 31 provides the ester 32, which on transacetoacetylation provides the -ketoamide 33. The other required precursor 38 is synthesized starting with L-cysteine 35, which is converted to the cyclic form 36 followed by methylation to provide the ester 37. The nucleophilic substitution of 37 with tert-butyl acetoacetate affords the -ketoamide 38. The diketene-acetone adduct 34 has also provided the -ketoamide 33 in comparable yields (Scheme 9).

Scheme 9

Reagents and conditions: i) SOCl2, MeOH; ii) TBAA, DMSO; iii) HCHO, H2O.

The precursors with -ketoamide functionality (33, 38) are utilized in the synthesis of substituted dihydropyrimidones by employing multicomponent Biginelli reaction, which is of growing importance in drug discovery process. The three-component condensation of -ketoamides (33, 38), substituted benzaldehydes (39-43) and thiourea 44 is catalyzed by cerium chloride to afford the monastrol based dihydropyrimidones (45-54) as depicted in Scheme 10. In the present work the structural modifications on the monastrol backbone are carried out at the ester moiety at C-5 position and aryl group at C-4 position. 
Scheme 10


Reagents and conditions: i)CeCl3. 7H2O, CH3CN.
The myristicin aldehyde (41) required in the synthesis of the dihydro pyrimidones with proline and thiazolidine ring (47, 52) has been prepared starting with vanillin (40), which on bromination has provided the 5-bromovanillin (55). The hydrolysis of 55 provides 3-methoxy-4, 5-dihydroxy benzaldehyde (56), which on methylenation affords myristicin aldehyde (41) in good yield (Scheme 11).
Scheme 11

Reagents and conditions: i) Br2, CH3COOH; ii) NaOH, Cu powder, H2O; iii) CH2Br2, CsCO3, DMF
The monastrol based dihydropyrimidones 45-48, 50 and 51 have been selected by Development Therapeutic Program of National Cancer Institute (NCI) and tested for a 60 human tumour cell line screen. Almost all the compounds have shown growth inhibition on SNB-75 cell line of central nervous system sub-panel in a range of 22.55-25.01% at 10M concentration. The compound 51 has been found to be the most active from this series, particularly selective against leukemia. It has displayed good cytotoxic potency against SR cell line of leukemia sub-panel with inhibitory effect of 53.28%, whereas against HL-60 (TB) and RPMI-8226 cell line it has exhibited 43.20%, and 27.14% inhibition, respectively. The in vitro cytotoxic evaluation of the compounds 49, 52-54 has been carried out on selected human cancer cell lines of lung, breast, skin and colon.
Section-B: Synthesis and Biological Evaluation of Conformationally Flexible as well as Restricted Dimers of Monastrol and Related Dihydropyrimidones 
This section deals with the synthesis of dimers of monastrol and related dihydropyrimidones and their evaluation for cytotoxic as well as DNA interactive abilities. The dimers are with flexible alkyl chains spacers of varying length and conformationally restricted spacers with unsaturation (cis and trans). The key intermediates with dibenzaldehyde group (58a-e, 59a-e) required for the synthesis of dimers of monastrol and related dihydropyrimidones are prepared by the condensation of the corresponding substituted aromatic aldehyde (57, 40) with dibromo aliphatic compounds (Scheme 12). 
Scheme 12

Reagents and conditions: i) Dibromo compound, and. K2CO3, cat. KI, CH3CN.
	The substituted dibenzaldehydes 58a-e are subjected to Lewis acid catalyzed bignelli cyclocondensation with 1, 3-dicarbonyl ester (ethyl acetoacetate 60), thiourea 44 and 1, 3-dicarbonyl amide with proline ring 33 to provide the symmetric dimers of monastrol 61a-e and asymmetric dimers 62a-e, respectively. Similarly, the substituted dibenzaldehydes 59a-e has provided the symmetric 63a-e and asymmetric dimers 64a-e of monastrol related dihydropyrimidones as depicted in Scheme 13. 
Scheme 13


Reagents and conditions:  i) CeCl3.7H2O, CH3CN.
The dimers have been evaluated for in vitro cytotoxic potency on selected human cancer cell lines of lung, breast, skin and colon. Some of the dimers have exhibited encouraging cytotoxicity against MCF-7 (breast) and A431 (skin) cancer cell lines. The dimer of monastrol 61a with three carbon spacer and the dimer 61d with cis unsaturation have shown an IC50 value of 19 and 49 g/mL for MCF-7 cell line, respectively. Amongst the dimers of monastrol related dihydropyrimidones, the dimers with trans unsaturated spacer (63e and 64e) are found to be most active from the series. The dimer 63e has shown an IC50 value of 35 g/mL against MCF cancer cell lines, whereas the dimer 64e has shown similar cytotoxicity (IC50 = 34 g/mL) against A431 cancer cell line. The DNA interactive ability of these dimers is under progress.





